Abstract
SUMMARY: Temozolomide, an oral alkylating agent, is a commonly used medicine in the treatment of anaplastic astrocytoma and glioblastoma multiforme. This paper will present the mechanism of action as well as the clinical role for this chemotherapeutic drug.
Abbreviations
- FDA
- US Food and Drug Administration
- MTIC
- methyl triazeno imidazole carboxamide
- Copyright © American Society of Neuroradiology
In this issue
Jump to section
Related Articles
Cited By...
- Functional Genomic Screens Reveal RBBP4 as a Key Regulator of Cell Cycle Progression in TMZ-Resistant Glioblastoma
- Vanishing bile duct syndrome: a sequela of temozolomide and levetiracetam-induced cholestatic liver injury
- Differential expression of GABARAPs in GBM renders temozolomide sensitivity in a p53-dependent manner
- Modelling glioblastoma resistance to temozolomide. Combination of spheroid and mathematical models to simulate cellular adaptation in vitro
- Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity